Company news
Promis Neurosciences Inc. (NASDAQ:PMN) news
Every Promis Neurosciences Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
September 1, 2026
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
August 13, 2026
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
August 3, 2026
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer...
July 28, 2026
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheim...
July 27, 2026
ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026
July 14, 2026
ProMIS Neurosciences to Participate in Upcoming Conferences in June
May 28, 2026
ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights
May 12, 2026
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 13, 2026
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights
March 25, 2026
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International C...
March 18, 2026
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
January 30, 2026
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
December 18, 2025
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical B...
December 10, 2025
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Su...
December 1, 2025
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
December 1, 2025
ProMIS Neurosciences Announces Reverse Stock Split
November 24, 2025
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights
November 12, 2025
ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
November 3, 2025
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of ...
October 22, 2025
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
September 3, 2025
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
August 13, 2025
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association...
July 29, 2025
ProMIS Neurosciences Announces Private Placement Financing
July 28, 2025
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
July 22, 2025
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
July 21, 2025
ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
June 17, 2025
ProMIS Neurosciences Announces First Quarter 2025 Financial Results
May 12, 2025
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
March 31, 2025
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s D...
March 24, 2025
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Ne...
March 13, 2025
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
March 11, 2025
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
February 25, 2025
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
January 29, 2025
ProMIS Neurosciences Issues Letter to Shareholders
January 13, 2025
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
January 10, 2025
ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights
November 14, 2024
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclini...
September 12, 2024
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 5, 2024
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica a...
August 6, 2024
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
August 1, 2024
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
July 26, 2024
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
July 26, 2024
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
May 14, 2024
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
April 30, 2024
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Targe...
April 9, 2024
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
April 4, 2024
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
April 1, 2024
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
March 11, 2024